Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Exelixis stock

Learn how to easily invest in Exelixis stock.

Exelixis Inc (EXEL) is a leading biotechnology business based in the US. It opened the day at $15.99 after a previous close of $15.89. During the day the price has varied from a low of $15.68 to a high of $16.22. The latest price was $15.90 (25 minute delay). Exelixis is listed on the NASDAQ and employs 954 staff. All prices are listed in US Dollars.

How to buy shares in Exelixis

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EXEL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Exelixis stock price (NASDAQ: EXEL)

Use our graph to track the performance of EXEL stocks over time.

Exelixis shares at a glance

Information last updated 2022-09-27.
Open$15.99
High$16.22
Low$15.68
Close$15.90
Previous close$15.89
Change $0.01
Change % 0.0629%
Volume 2,264,297
Information last updated 2022-09-25.
52-week range$15.50 - $23.40
50-day moving average $19.27
200-day moving average $19.77
Wall St. target price$27.46
PE ratio 19.381
Dividend yield $0 (0%)
Earnings per share (TTM) $0.84

Buy Exelixis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Exelixis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Exelixis price performance over time

Historical closes compared with the close of $15.9 from 2022-09-27

1 week (2022-09-21) -3.64%
1 month (2022-08-26) -12.78%
3 months (2022-06-28) -24.07%
6 months (2022-03-24) N/A
1 year (2021-09-27) -23.19%
2 years (2020-09-28) -33.00%
3 years (2019-09-27) 17.995
5 years (2017-09-28) 24.23

Is Exelixis stock undervalued or overvalued?

Valuing Exelixis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exelixis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Exelixis's P/E ratio

Exelixis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Exelixis shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Exelixis's PEG ratio

Exelixis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3259. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exelixis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Exelixis's EBITDA

Exelixis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $351.2 million.

The EBITDA is a measure of a Exelixis's overall financial performance and is widely used to measure a its profitability.

Exelixis financials

Revenue TTM $1.6 billion
Operating margin TTM 21.56%
Gross profit TTM $1.4 billion
Return on assets TTM 7.98%
Return on equity TTM 12.3%
Profit margin 17.53%
Book value $7.43
Market capitalisation $5.2 billion

TTM: trailing 12 months

Exelixis share dividends

We're not expecting Exelixis to pay a dividend over the next 12 months.

Exelixis share price volatility

Over the last 12 months, Exelixis's shares have ranged in value from as little as $15.5 up to $23.4. A popular way to gauge a stock's volatility is its "beta".

EXEL.US volatility(beta: 0.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exelixis's is 0.6484. This would suggest that Exelixis's shares are less volatile than average (for this exchange).

Exelixis overview

Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc.

Frequently asked questions

What percentage of Exelixis is owned by insiders or institutions?
Currently 2.159% of Exelixis shares are held by insiders and 89.91% by institutions.
How many people work for Exelixis?
Latest data suggests 954 work at Exelixis.
When does the fiscal year end for Exelixis?
Exelixis's fiscal year ends in January.
Where is Exelixis based?
Exelixis's address is: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
What is Exelixis's ISIN number?
Exelixis's international securities identification number is: US30161Q1040
What is Exelixis's CUSIP number?
Exelixis's Committee on Uniform Securities Identification Procedures number is: 30161Q104

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site